Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orteronel + docetaxel + prednisone
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a **combination regimen** of three agents—orteronel, docetaxel, and prednisone—investigated primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC). - **Orteronel (TAK-700)** is an investigational, selective, non-steroidal inhibitor of 17,20-lyase, thereby reducing androgen production, including testosterone and dehydroepiandrosterone-sulfate (DHEA-S)[1][2][4]. - **Docetaxel** is a taxane-class antineoplastic agent that promotes tubulin polymerization and inhibits depolymerization, thus inhibiting cell division and causing cancer cell death. - **Prednisone** is a synthetic glucocorticoid used here to manage side effects of chemotherapy and possibly enhance anti-tumor efficacy. This three-drug regimen was studied in a phase 1/2 clinical trial for mCRPC, targeting separate but complementary pathways in prostate cancer pathogenesis: androgen biosynthesis, mitotic activity, and immune/inflammation modulation[1][2][5].
- Other names
- orteronel + docetaxel + prednisone
02
Targets
GR (Glucocorticoid receptor)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on orteronel + docetaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orteronel + docetaxel + prednisone.